Skip to main content

Table 4 WOMAC pain scores by group and visit

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

    Group
    UP446
250 mg/day
UP446
500 mg/day
Celecoxib
200 mg/day
Placebo
Visit Baseline Mean 3.17 3.41 3.20 2.97
   Std Deviation 0.80 0.93 0.89 0.60
  30 Days Mean 2.65 2.44 3.00 2.67
   Std Deviation 0.77 0.92 0.92 0.62
  60 Days Mean 2.63 2.63 2.20 3.29
   Std Deviation 0.66 0.79 0.66 0.67
  90 Days Mean 2.67 2.11 2.27 3.00
   Std Deviation 0.65 0.86 0.66 0.58